Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
62 studies found for:    "Multiple Sclerosis, Chronic Progressive"
Show Display Options
Download search resultsDownload the search results for:
"Multiple Sclerosis, Chronic Progressive" (62 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Active, not recruiting Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)
Condition: Multiple Sclerosis, Chronic Progressive
Interventions: Drug: lipoic acid;   Drug: Placebo
2 Completed Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis, Chronic Progressive
Interventions: Drug: Cyclophosphamide (drug);   Drug: Methylprednisolone (drug)
3 Unknown  Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis
Conditions: Multiple Sclerosis, Chronic Progressive;   Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: RTL1000 (recombinant T cell receptor ligand);   Drug: RTL1000 Placebo
4 Active, not recruiting China Betaferon Adherence, Coping and Nurse Support Study
Condition: Multiple Sclerosis, Chronic Progressive
Intervention: Drug: Interferon beta-1b (Betaseron, BAY86-5046)
5 Unknown  Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients
Conditions: Relapsing Remitting Multiple Sclerosis;   Multiple Sclerosis, Chronic Progressive
Intervention: Drug: Ritalin
6 Completed Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis
Conditions: Secondary Progressive Multiple Sclerosis;   Primary Progressive Multiple Sclerosis
Intervention: Biological: MIS416
7 Active, not recruiting A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis, Primary Progressive
Interventions: Drug: Placebo;   Drug: methylprednisolone;   Drug: ocrelizumab
8 Active, not recruiting FTY720 in Patients With Primary Progressive Multiple Sclerosis
Condition: Primary Progressive Multiple Sclerosis
Interventions: Drug: FTY720;   Drug: Placebo
9 Recruiting A Phase 2b/3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis
Conditions: Multiple Sclerosis, Secondary Progressive;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Relapse Free
Interventions: Drug: masitinib;   Drug: placebo
10 Completed Natalizumab Treatment of Progressive Multiple Sclerosis
Conditions: Primary Progressive Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
Intervention: Drug: Natalizumab
11 Recruiting ACTH in Progressive Forms of MS
Conditions: Secondary Progressive Multiple Sclerosis;   Primary Progressive Multiple Sclerosis;   Progressive Relapsing Multiple Sclerosis
Interventions: Drug: ACTH;   Drug: Placebo
12 Recruiting OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Condition: Primary Progressive Multiple Sclerosis
Intervention: Drug: FTY720
13 Terminated Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis, Secondary Progressive
Intervention: Drug: MBP8298
14 Recruiting A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
Condition: Primary Progressive Multiple Sclerosis
Interventions: Drug: Laquinimod;   Drug: Placebo
15 Recruiting Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
Condition: Secondary Progressive Multiple Sclerosis
Interventions: Drug: BAF312;   Drug: Placebo
16 Recruiting Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis
Condition: Secondary Progressive Multiple Sclerosis
Interventions: Procedure: Blood Draw;   Procedure: CSF collection by lumbar puncture (Optional)
17 Recruiting A Trial to Compare the Effectiveness of Two Rehabilitation Programs for Multiple Sclerosis Patients
Conditions: Primary Progressive Multiple Sclerosis,;   Secondary Progressive Multiple Sclerosis;   Relapsing-remitting Multiple Sclerosis,;   Demyelinating Autoimmune Diseases,;   Nervous System Diseases
Interventions: Behavioral: Combined program;   Behavioral: Physiotherapy in private practice
18 Recruiting Functional Electrical Stimulation for Individuals With Secondary Progressive Multiple Sclerosis
Condition: Secondary Progressive Multiple Sclerosis
Intervention: Behavioral: exercise training
19 Recruiting Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis
Conditions: Relapsing Remitting Multiple Sclerosis;   Secondary-progressive Multiple Sclerosis;   Cognitive Deficits;   Motor Deficits
Intervention: Device: tDCS
20 Active, not recruiting A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
Condition: Secondary Progressive Multiple Sclerosis
Interventions: Drug: BG00002 (Natalizumab);   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years